The Coapsys device to treat functional mitral regurgitation: In vivo long-term canine study

Citations of this article
Mendeley users who have this article in their library.


Objective: We evaluated the capability of the Myocor Coapsys device (Myocor. Inc. Maple Grove, Minn) to reduce functional mitral regurgitation in a canine model of dilated cardiomyopathy. Methods: Functional mitral regurgitation with heart failure was induced in 7 dogs by rapid ventricular pacing. The Coapsys device. which consists of anterior and posterior epicardial pads connected by a subvalvular chord, was then implanted. Heart failure was maintained by continued pacing for 8 weeks. Hemodynamic and echocardiographic measurements were performed at pre- and post-sizing and after 8 weeks. The Coapsys subvalvular chord was cut to verify that maintenance of valve competency was due to the device. Results: All implants were performed off-pump without atriotomy. Mitral regurgitation was reduced in all animals; mean mitral regurgitation grade was reduced from 2.9 ± 0.7 to 0.7 ± 0.8 (P = .00005) and was maintained at 0.8 ± 0.8 after 8 weeks, without hemodynamic compromise or structural damage to the mitral valve. Mitral regurgitation returned to 3.6 ± 0.8 (P = .102 versus presizing) after cutting the Coapsys subvalvular chord. Conclusion: The Coapsys device consistently and chronically reduced functional mitral regurgitation. This device is in clinical trials in the United States.




Inoue, M., McCarthy, P. M., Popović, Z. B., Doi, K., Schenk, S., Nemeh, H., … Filsoufi, F. (2004). The Coapsys device to treat functional mitral regurgitation: In vivo long-term canine study. Journal of Thoracic and Cardiovascular Surgery, 127(4), 1068–1077.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free